Cancer researchers have demonstrated a method to reprogram tumour cells into benign cells in what could be a dramatic breakthrough in the fight against the disease.
Scientists warn the method has only been trialled ‘in vitro’, and has not been tested on live human patients. But the hope is the technique may lead to a treatment for different cancers far less destructive than chemotherapy.
Cancer cells are essentially the same as normal cells, but instead of stopping the process of division during replication, they continue to divide. The result is a tumour. The instruction to stop dividing is usually controlled by microRNAs, small but critical biological markers within the cells, but something happens inside cancerous cells which stops that process.
The team at the Mayo Clinic in Florida found that by injecting human breast and bladder cancer cells with PLEKHA7 — the protein thought to stop cells dividing when added in the right quantities — they could transform cancer cells into benign cells. The insight into the role of PLEKHA7 helped the team understand how the behaviour of proteins E-cadherin and p120 catenin, which are critical for holding normal tissue together while also powering cancer division, could be regulated.
“We should be able to re-establish the brakes and restore normal cell function,” professor Panos Anastasiadis, of the Department for Cancer Biology at Mayo told The Telegraph. “Initial experiments in some aggressive types of cancer are indeed very promising.”
The study, published in Nature Cell Biology, is in theory a dramatic discovery, and if applicable in human trials would give doctors the ability to tell tumours to stop growing entirely.
“The study brings together two so-far unrelated research fields — cell-to-cell adhesion and miRNA biology — to resolve a long-standing problem about the role of adhesion proteins in cell behavior that was baffling scientists,” lead author Antonis Kourtidis said in a press statement “Most significantly, it uncovers a new strategy for cancer therapy.”
The Latest on: Reprogram tumour cells
via Google News
The Latest on: Reprogram tumour cells
- New technique can measure metabolic process at the single-cell levelon June 18, 2021 at 7:58 pm
Understanding cellular metabolism - how a cell uses energy- could be key to treating a wide array of diseases, including vascular diseases and cancer.
- Next-generation T-cell therapeutics set sights on cancers, autoimmune disorders and moreon June 18, 2021 at 7:20 am
T cells—immune cells that patrol our bodies in search of trouble—have become a central focus for UC San Francisco scientists working on living cell therapies, an approach that views cells themselves ...
- Metabolic Processes Visualized at the Single-Cell Levelon June 18, 2021 at 3:02 am
It also has important implications in treating cancer. Endothelial migration and proliferation ... distress syndrome at Argonne National Laboratory. "Can we ultimately reprogram cells through ...
- For the first time, researchers visualize metabolic process at the single-cell levelon June 18, 2021 at 12:07 am
Understanding cellular metabolism—how a cell uses energy—could be key to treating a wide array of diseases, including vascular diseases and cancer.
- Presence of certain stem cells linked to nongenetic resistance mechanisms of cancer cellson June 17, 2021 at 9:30 pm
Cancer cells can develop resistance to therapy through both genetic and non-genetic mechanisms. But it is unclear how and why one of these routes to resistance prevails.
- Lyell, Verve IPOs raise a combined $692M as both biotechs steer toward clinical trialson June 17, 2021 at 4:29 pm
Lyell Immunopharma and Verve Therapeutics are still preclinical, but they're bring novel genetic approaches to the treatment of cancer and cardiovascular disease. Now the two companies can claim two ...
- For first time, researchers visualize metabolic process at single-cell levelon June 17, 2021 at 1:44 pm
While many techniques can measure these processes among tens of thousands of cells, researchers have been unable to measure them at the single-cell level. Researchers at the University of Chicago’s ...
- Predicting resistance to anticancer drugson June 17, 2021 at 8:00 am
Cancer cells can develop resistance to therapy through ... These cells literally reprogram themselves to evade the therapeutic pressure. The researchers also identified the signaling pathway ...
- Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platformon June 15, 2021 at 9:00 pm
Mnemo Therapeutics, a biotechnology company developing powerful cell therapies using a novel target identification engine, stronger T cells ...
- Sugar Nanoparticles Reprogram Immune Cells to Help Destroy Tumorson June 10, 2021 at 5:00 pm
For the cargo, the researchers screened a panel of 38 drugs that have been known to reprogram macrophages ... and worked with T-cells to destroy the implanted tumors in mice.
via Bing News